В России создадут аналог американского препарата «Зепатир» против гепатита С

American MSD decided to stop supplying "Zepatir" to Russia, although it is one of the key drugs against hepatitis C

The Ministry of Industry and Trade announced that several domestic companies are working on an analogue of the American drug "Zepatir" against hepatitis C.

The drug "Zepatir" is under patent in the Russian Federation until March 2030. According to operational information, several domestic enterprises are developing a reproduced drug.
Ministry of Industry and Trade

Earlier, the Kommersant publication reported that American MSD decided to stop supplying "Zepatir" to Russia. But this is one of the most popular drugs, accounting for almost 20% of all public procurement of drugs for this disease. And although there are other drugs against hepatitis C in Russia, "Zepatir" is one of the most affordable and effective. Therefore, the emergence of a domestic analogue is extremely important.

To support the creation of popular analogues of drugs from the list of vital necessities, but under patent protection, the "products on the shelf" mechanism has been introduced since 2023. In accordance with it, Russian companies will receive subsidies on a competitive basis for the development and registration of drugs for medical use, protected by patents in Russia.

The Ministry of Health reported that the Russian company "R-Pharm" has a sufficient supply of "Zepatir" - the drug will last until 2025.

As a reminder, a modern pharmaceutical production facility with a capacity of 270 million packages of drugs per year opened yesterday in Moscow.

Now on home